Abvc Biopharma (ABVC) Total Liabilities (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Total Liabilities came in at $6.9 million in Q1 2026, little changed YoY from $6.9 million in Q1 2025, and down 11.08% on a QoQ basis from $7.8 million in Q4 2025.
Abvc Biopharma (ABVC) Total Liabilities (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of Total Liabilities data on file, last reported at $6.9 million in Q1 2026.
- Quarterly Total Liabilities changed 0.22% year-over-year to $6.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (changed 0.22% YoY) and the FY2025 annual result came in at $7.8 million, up 13.92% from the prior year.
- Total Liabilities eased to $6.9 million in Q1 2026, from $7.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $9.7 million in Q2 2023 to a low of $4.6 million in Q2 2022.
- A 5-year average of $6.7 million and a median of $6.7 million in 2025 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities tumbled 46.51% — and 2023, when it surged 110.5%.
- Tracing ABVC's Total Liabilities over 5 years: stood at $6.3 million in 2022, then grew by 2.96% to $6.5 million in 2023, then advanced by 4.36% to $6.8 million in 2024, then gained by 13.92% to $7.8 million in 2025, then dropped by 11.08% to $6.9 million in 2026.
- The last three Total Liabilities figures came in at $6.9 million (Q1 2026), $7.8 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 10.03 Bn |
| 10 | Abvc Biopharma | 24.23 Mn | 24.23 Mn | - | 7.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.13 Mn |
| Mar 31, 2026 | 6.90 Mn |
| Dec 31, 2025 | 7.76 Mn |
| Sep 30, 2025 | 6.72 Mn |
| Jun 30, 2025 | 6.75 Mn |
| Mar 31, 2025 | 6.92 Mn |
| Dec 31, 2024 | 6.82 Mn |
| Sep 30, 2024 | 6.44 Mn |
| Jun 30, 2024 | 6.50 Mn |
| Mar 31, 2024 | 6.52 Mn |
| Dec 31, 2023 | 6.53 Mn |
| Sep 30, 2023 | 7.53 Mn |
| Jun 30, 2023 | 9.69 Mn |
| Mar 31, 2023 | 9.00 Mn |
| Dec 31, 2022 | 6.34 Mn |
| Sep 30, 2022 | 4.79 Mn |
| Jun 30, 2022 | 4.60 Mn |
| Mar 31, 2022 | 4.71 Mn |
| Dec 31, 2021 | 4.83 Mn |
| Sep 30, 2021 | 4.77 Mn |